Xian Yihang Technology
Xian Yihang Technology's purity-focus evidence is strongest in BPC-157 and recent Tirzepatide rebounds, while Retatrutide and GHK-Cu expose the main weaknesses. Results are dispersed rather than uniform, with mixed recent purity, a GHK-Cu identity/fill outlier, and sparse batch IDs limiting traceability despite current, moderate-volume evidence.
Platform records tie the eCHEMI supplier, Yihang Biochemical site, and TopXPeptide/YH Peptide retail brand through shared contacts, domains, and Xi'an addresses. The report also traces a missing first shop, unverified certification claims, and a catalog that reaches into regulated drug compounds.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Xian Yihang Technology rows.
Cancel anytime
| Date | Result | Test | Lab | Purity | Dosage | Label | COA |
|---|---|---|---|---|---|---|---|
| 13 Jul 2026 | Fail | Semaglutide Xian Yihang Technology | lab name | View COA | |||
| 9 Jul 2026 | Pass | Retatrutide Xian Yihang Technology | lab name | View COA | |||
| 24 Jun 2026 | Pass | BPC-157 Xian Yihang Technology | lab name | View COA | |||
| 22 Jun 2026 | Pass | Tirzepatide Xian Yihang Technology | lab name | View COA | |||
| 8 Jun 2026 | Pass | Tirzepatide Xian Yihang Technology | lab name | View COA | |||
| 1 Jun 2026 | Pass | Tirzepatide Xian Yihang Technology | lab name | View COA | |||
| 1 Jun 2026 | Pass | Tirzepatide Xian Yihang Technology | lab name | View COA | |||
| 23 Apr 2026 | Pass | Retatrutide Xian Yihang Technology | lab name | View COA | |||
| 23 Apr 2026 | Pass | Tirzepatide Xian Yihang Technology | lab name | View COA | |||
| 23 Apr 2026 | Pass | Retatrutide Xian Yihang Technology | lab name | View COA | |||
About Xian Yihang Technology test results from Finnrick
Xian Yihang Technology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 77 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Xian Yihang Technology peptides in this dataset are BPC-157 (5 tests) and Semaglutide (4 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 77 recent tests.